San Francisco Bay Area biotech stories.
Thursday, July 26, 2012
Genentech's Lucentis recommended for approval for diabetic eye disease
An FDA advisory panel recommended Thursday that
Inc.'s eye drug Lucentis be approved for some diabetes patients who have lost their sight
. Already approved for age-related macular degeneration, Lucentis' approved use could extend to patients with diabetic macular degeneration if the Food and Drug Administration approves the new application by Aug. 10.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)